You are here: Home: Audio Program Guide: LCU 1 | 2006 Audio: LCU 1 | 2006

 
   
  To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Thomas J Lynch, MD
Director, MGH Thoracic Oncology Center
Deputy Chief, Hematology Oncology
Associate Professor of Medicine Massachusetts General Hospital
Boston, Massachusetts
  
  Click here to download the entire interview  
Track 1 Introduction by Neil Love, MD
Track 2 Predictors of response to EGFR TKIs in NSCLC
Track 3 Development of the Colorado Index to assist in therapy selection
Track 4 Phase II study of gefitinib in treatment-naïve patients with Stage IIIB-IV NSCLC and EGFR mutations
Track 5 Nonsmoking status as a predictor of response to EGFR TKIs
Track 6 Designing and targeting therapies in NSCLC based on oncogenic signatures
Track 7 Research strategies to evaluate EGFR TKIs in the adjuvant setting
Track 8 Use of adjuvant TKIs in nonsmoking patients or those with the EGFR mutation
Track 9 Mutations as a means for discerning mechanisms of therapeutic resistance
Track 10 Case discussion: A 51-year-old nonsmoking woman with metastatic NSCLC treated with carboplatin/paclitaxel plus bevacizumab
Track 11 Risk of hemoptysis in patients with central or squamous cell tumors treated with bevacizumab
Track 12 Potential mechanisms of bevacizumab-associated hemoptysis
Track 13 ECOG-E4599 and the effect of bevacizumab on patients with NSCLC
Track 14 Use of bevacizumab in combination with other chemotherapeutic agents
Track 15 Clinical investigations of bevacizumab in the adjuvant setting
Track 16 Selection of adjuvant chemotherapy regimens
Track 17 Selection of patients with Stage IA disease to receive adjuvant chemotherapy
Track 18 Potential utility of neoadjuvant versus adjuvant chemotherapy
Track 19 Therapeutic approach to patients with Stage III NSCLC
Track 20 SWOG-S9504: Consolidation docetaxel after chemoradiotherapy in Stage IIIB NSCLC
Track 21 Future clinical trial challenges in advancing adjuvant therapy in NSCLC
     
Kathy S Albain, MD
Professor of Medicine
Loyola University Stritch School of Medicine
Clinical Director, Breast Cancer Research
Co-Director, Breast Care Center
Director, Thoracic Oncology Center Chicago, Illinois
  
  Click here to download the entire interview  
Track 1 Introduction by Neil Love, MD
Track 2 ECOG-E4599: Translating first-line bevacizumab data into clinical practice
Track 3 Selection of first-line therapy for patients ineligible for ECOG-E4599
Track 4 Incorporating erlotinib into the management of metastatic NSCLC
Track 5 Identifying predictors of response to EGFR TKIs
Track 6 Use of adjuvant chemotherapy in patients with lower-risk disease
Track 7 Incorporating targeted therapies into adjuvant clinical trials
Track 8 Continuation of bevacizumab after disease progression
Track 9 RTOG-9309: Radiotherapy concurrent with cisplatin/etoposide with or without surgical resection in Stage IIIA NSCLC
Track 10 RTOG-9309: Higher mortality associated with pneumonectomy
Track 11 Docetaxel consolidation after induction chemoradiation in Stage IIIB disease
Track 12 Chemoradiation therapy for patients with Stage III disease
Track 13 SWOG-S0229: Pulmonary rehabilitation education with or without exercise training
     
Richard J Gralla, MD
President
New York Lung Cancer Alliance
New York, New York
  
  Click here to download the entire interview  
Track 1 Introduction by Neil Love, MD
Track 2 Advances in chemotherapy for metastatic NSCLC
Track 3 Comparison of platinum agents in the treatment of NSCLC
Track 4 Choice of chemotherapy in combination with cisplatin or carboplatin
Track 5 ECOG-E4599: Carboplatin/paclitaxel with or without'] bevacizumab in advanced, nonsquamous cell NSCLC
Track 6 Bevacizumab-associated side effects in ECOG-E4599
Track 7 Clinical implications of ECOG-E4599
Track 8 EGFR mutation as a predictor of response to TKIs
Track 9 Nonsmoking as a predictor of response to TKIs
Track 10 Selection of patients for treatment with TKIs with or without chemotherapy
Track 11 Pooled analysis of 12 studies: Survival and magnitude of benefit from adjuvant chemotherapy
Track 12 Selection of the optimal adjuvant chemotherapeutic regimen
Track 13 Recent neoadjuvant clinical trial results in patients with Stage III disease
Track 14 SWOG-S0023: Concurrent chemoradiotherapy followed by consolidation docetaxel and gefitinib/placebo maintenance in unresectable Stage III NSCLC
Track 15 Topoisomerase inhibitors and cisplatin in the treatment of extensive SCLC
Track 16 Imatinib in patients with c-kit-expressing relapsed SCLC
Track 17 Adjuvant versus neoadjuvant therapy in NSCLC